Panamera Holdings Corporation (PHCI)
USD 1.75
(0.0%)
USD 1.75
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.12 Million USD | -21808.4% |
| 2022 | -32.5 Thousand USD | 64.18% |
| 2021 | -90.74 Thousand USD | -244.82% |
| 2020 | -26.31 Thousand USD | 1.85% |
| 2019 | -26.81 Thousand USD | 4.96% |
| 2018 | -28.21 Thousand USD | -12.43% |
| 2017 | -25.09 Thousand USD | 53.81% |
| 2016 | -54.32 Thousand USD | 27.43% |
| 2015 | - USD | -16104.76% |
| 2014 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -62.07 Thousand USD | 99.13% |
| 2024 Q2 | -41.37 Thousand USD | 33.59% |
| 2024 Q3 | -7.5 Million USD | -18115.95% |
| 2023 Q2 | -11.43 Thousand USD | -237.4% |
| 2023 Q3 | -8146.00 USD | 28.74% |
| 2023 Q4 | -7.09 Million USD | -87031.14% |
| 2023 FY | - USD | -21808.4% |
| 2023 Q1 | -3388.00 USD | 19.58% |
| 2022 Q3 | -19.61 Thousand USD | -214.45% |
| 2022 FY | - USD | 64.18% |
| 2022 Q4 | -4213.00 USD | 78.52% |
| 2022 Q2 | -6237.00 USD | -155.61% |
| 2022 Q1 | -2440.00 USD | 96.53% |
| 2021 Q3 | -5105.00 USD | -8.99% |
| 2021 FY | - USD | -244.82% |
| 2021 Q4 | -70.22 Thousand USD | -1275.59% |
| 2021 Q1 | -10.73 Thousand USD | -118.48% |
| 2021 Q2 | -4684.00 USD | 56.37% |
| 2020 Q4 | -4914.00 USD | 6.19% |
| 2020 FY | - USD | 1.85% |
| 2020 Q1 | -11.53 Thousand USD | -120.27% |
| 2020 Q2 | -4635.00 USD | 59.8% |
| 2020 Q3 | -5238.00 USD | -13.01% |
| 2019 Q4 | -5235.00 USD | -15.33% |
| 2019 FY | - USD | 4.96% |
| 2019 Q2 | -5728.00 USD | 49.36% |
| 2019 Q3 | -4539.00 USD | 20.76% |
| 2019 Q1 | -11.31 Thousand USD | -150.47% |
| 2018 Q3 | -5361.00 USD | 11.04% |
| 2018 FY | - USD | -12.43% |
| 2018 Q2 | -6026.00 USD | 51.04% |
| 2018 Q1 | -12.3 Thousand USD | -122.87% |
| 2018 Q4 | -4516.00 USD | 15.76% |
| 2017 Q1 | -8241.00 USD | 67.51% |
| 2017 FY | - USD | 53.81% |
| 2017 Q4 | -5523.00 USD | -20.99% |
| 2017 Q3 | -4565.00 USD | 32.51% |
| 2017 Q2 | -6764.00 USD | 17.92% |
| 2016 Q3 | -17.12 Thousand USD | -451.3% |
| 2016 Q1 | -13.23 Thousand USD | 62.29% |
| 2016 Q2 | -3107.00 USD | 76.52% |
| 2016 FY | - USD | 27.43% |
| 2016 Q4 | -25.36 Thousand USD | -48.06% |
| 2015 Q4 | -35.08 Thousand USD | -399.67% |
| 2015 FY | - USD | -16104.76% |
| 2015 Q3 | -7021.00 USD | -1.18% |
| 2015 Q2 | -6939.00 USD | 66.02% |
| 2015 Q1 | -20.41 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Oncology Network, Inc. | -39.35 Million USD | 81.905% |
| ATI Physical Therapy, Inc. | 82.86 Million USD | 108.593% |
| Assure Holdings Corp. | -19.82 Million USD | 64.081% |
| Novo Integrated Sciences, Inc. | -5.84 Million USD | -21.742% |